Proteomics International Laboratories (PIQ) investor relations material

Executive summary

• FY2026 marked a transition from research-led development to commercial execution, with a focus on the Promarker® diagnostic portfolio and operational discipline.

• The company launched Promarker D and Promarker Eso in Australia, advanced Promarker Endo, and entered a national distribution agreement with Healius for broader market access.

• Leadership changes included the appointment of a new CEO and a significant organisational restructure, resulting in cost savings and improved commercial focus.

Financial highlights

• Total revenue and other income rose 3.0% to $3.61 million, including $2.17 million from the R&D Tax Incentive.

• Net loss after tax increased 5.5% year-over-year to $8.56 million, reflecting ongoing investment in commercialisation and development.

• Net cash used in operating activities was $5.87 million; cash and cash equivalents at year-end were $3.50 million.

• Net tangible assets per share declined to 3.27 cents from 7.94 cents the prior year.

• No dividends were declared or paid.

Outlook and guidance

• FY2027 priorities include implementing the Healius agreement, refining go-to-market strategies for Promarker D and Eso, preparing Promarker Endo for market, and progressing reimbursement in Australia and the US.

• Management will focus on capital discipline, laboratory quality, and expanding distribution partnerships.

• Timing and scale of revenue growth remain uncertain, dependent on adoption, reimbursement, and market conditions.